Secondary outcomes
Tecan
DISEASE PROGRESSION, DISEASE, PULMONARY INVOLVEMENT, SECONDARY, BLOOD
Blood tests planned to be conducted in the study were mainly of two types: (1) for assessment, monitoring the disease progression markers (PT-INR, Hs CRP, D-dimer, ferritin, cytokines, and other molecular markers) and observing the effect of trial medicines on them; (2) for identifying systemic effects of the disease as well as the effect of trial medication on the general safety of these parameters such as CBC, LFT, KFT, lipid profile. To evaluate these blood parameters, 16 ml venous blood was collected at three time points before the start of treatment, midway through treatment, and at the end of treatment. Hematological parameters, CBC, and ESR were analyzed on a 6-part hematology autoanalyzer (Sysmex XN 1000), and ESR analyzer (Vesmatic 80), respectively. Coagulation parameters (PT/INR/D-dimer) were analyzed by a fully automated coagulation analyzer (STAGO startmax). Biochemical parameters (LFT, KFT, lipid profile, ferritin, and hsCRP) were analyzed on a fully automated analyzer (Vitros XT 7600).Further serum samples were isolated and stored to measure 15 pro-inflammatory and anti-inflammatory cytokines (IFN-α2, IFN-γ, IL-1β, IL-1RA, IL-4, IL-6, IL-7, IL-8, IL-13, IL-18, IP-10, MCP-1, MCP-3, TNF-α, and VEGFA) levels through multiplexing (MILLIPLEX® MAP KIT; Cat.#HCYTA-60K), and the plate was scanned using MAGPIX with xPONENT software and measuring biomarkers such as HIF-1α (ELISA kit-Elabscience®; E-EL-H6066), and vWF (ELISA kit-Elabscience®; E-EL-H2168) and the plate was scanned using Tecan i-control, 2.0.10.0. All the experiments were performed by following the manufacturer's protocols. 67 patients' data with three time points were considered for the analysis of secondary outcomes.X-rays were also done for patients at the time of enrollment and at the end of the intervention period, to rule out any pulmonary involvement or progression during the course of disease in patients on treatment.